Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for pancreatic cancer: triple-drug combo enters human testing

NCT ID NCT06896188

Recruiting now Disease control Sponsor: Anwaar Saeed Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 17 times

Summary

This early-phase study tests whether adding two new drugs (elraglusib and retifanlimab) to standard chemotherapy can help people with advanced pancreatic cancer that hasn't been treated before. The main goal is to check safety and find the right dose. Up to 12 adults will take part. If safe, the combination might better control the disease, but it is not expected to be a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PANCREATIC ADENOCARCINOMA